2020
Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).
Ferris R, Flamand Y, Weinstein G, Li S, Quon H, Mehra R, Garcia J, Chung C, Gillison M, Duvvuri U, O'malley B, Ozer E, Thomas G, Koch W, Kupferman M, Bell R, Saba N, Lango M, Mendez E, Burtness B. Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311). Journal Of Clinical Oncology 2020, 38: 6500-6500. DOI: 10.1200/jco.2020.38.15_suppl.6500.Peer-Reviewed Original ResearchProgression-free survivalExtranodal extensionOropharynx cancerTransoral resectionPrimary endpointArm BArm AECOG-ACRIN Cancer Research GroupAdvanced oropharynx cancerTreatment-related deathsUninvolved surgical marginsArm DIntermediate-risk patientsLow-risk diseasePhase III trialsNon-surgical therapyGood oncologic outcomesPost-operative managementCancer Research GroupPost-operative therapyLow-dose radiationPostoperative RTDistant recurrenceFree survivalIII trials
2012
ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).
Marur S, Lee J, Cmelak A, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). Journal Of Clinical Oncology 2012, 30: 5566-5566. DOI: 10.1200/jco.2012.30.15_suppl.5566.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaInduction chemotherapySquamous cell carcinomaQuality of lifeCell carcinomaDay 1Primary siteMedian age 57 yearsResectable squamous cell carcinomaPhase II clinical trialCetuximab loading doseCisplatin 75mg/Pack-years smokingStandard-dose RTTumor stage T1Age 57 yearsHuman papillomavirus infectionPhase II trialProgression-free survivalExpression of biomarkersLow-dose radiationClinical CRRT armTarget accrualToxic regimens